US at a glance
- Population
- 341.8 million 2025
- Life expectancy at birth
- 78.9 years, 2024
- People aged 65 and over
- 18.4 % of people, 2025
- Health spending per person
- 13,473 US$ per person, 2023
- Doctors
- 3.68 per 1,000 people, 2022
US Antiviral Drugs Market Industry Trends and Forecast to 2034: Segmented by (Virus, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$2.46 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $23.55 Bn | — | — |
| 2025 (base) | $23.81 Bn | +$259.0 Mn | — |
| 2026 (forecast) | $24.07 Bn | +$261.9 Mn | +1.1% |
| 2027 (forecast) | $24.33 Bn | +$264.7 Mn | +2.2% |
| 2028 (forecast) | $24.60 Bn | +$267.7 Mn | +3.3% |
| 2029 (forecast) | $24.87 Bn | +$270.6 Mn | +4.5% |
| 2030 (forecast) | $25.14 Bn | +$273.6 Mn | +5.6% |
| 2031 (forecast) | $25.42 Bn | +$276.6 Mn | +6.8% |
| 2032 (forecast) | $25.70 Bn | +$279.6 Mn | +8% |
| 2033 (forecast) | $25.98 Bn | +$282.7 Mn | +9.1% |
| 2034 (forecast) | $26.27 Bn | +$285.8 Mn | +10.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $23.81 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $26.27 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 1.1% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Virus, route and end user (see all) |
| Key players | Gilead Sciences, Inc., GSK PLC, Merck & Co., Inc., Pfizer Inc., AbbVie Inc. and 1 more (see all) |
| Regulator in the US | FDASource: US Food and Drug Administration. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Antiviral drugs treat infections caused by viruses such as HIV, hepatitis, influenza, herpes and COVID-19.
Key segments of the antiviral Drugs market include virus (HIV, Hepatitis B and C and Influenza) and route (Oral, Injectable and Topical).
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the antiviral Drugs market.
New vaccines, rapid tests and public-private funding for neglected diseases give the antiviral Drugs market room to grow, especially in Asia, Africa and Latin America.
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the antiviral Drugs market.
The antiviral Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2]
[1] US Food and Drug Administration. Checked 14 Nov 2026.
[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for antiviral Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.
What doctors and scientists are doing in Antiviral Drugs right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.
From our blog
US · 2 shared keywords
US · 2 shared keywords
US · 2 shared keywords
US · 2 shared keywords
US · 2 shared keywords
US · 2 shared keywords
Medical Devices · US
Medical Devices · US
OTC & Nutraceuticals · US
Medical Devices · US
Healthcare Services · US
Medical Devices · US